ERBB3 and cancer: The emerging epigenetic approaches targeting HER3 and/or its signaling are theoretically based upon RNA interference (RNAi) technology-based therapy, such as “small interfering RNA” (siRNA)- or miRNA-replacement therapy, which is actively being explored as a new strategy to treat human diseases, including cancer [107].